Dr. Julie L. Gerberding to Retire from MSD
March 1, 2022 10:15 am ET
KENILWORTH, N.J.– MSD (NYSE: MRK), a trade name of Merck & Co., Inc., Kenilworth, NJ, USA, today announced that Dr. Julie L. Gerberding, chief patient officer and executive vice president, population health and sustainability, will be retiring from MSD in May 2022. Earlier today, the Foundation for the National Institutes of Health (FNIH) announced that Dr. Gerberding will become CEO of the FNIH on May 16.
“Julie’s accomplishments during her 12 years with MSD will have an impact on our company, our communities and the patients we serve that extends well beyond her tenure with us,” said Robert M. Davis, chief executive officer and president, MSD. “Julie embraced and embodied MSD’s commitment to patients and to our purpose to save and improve lives. Julie has been instrumental in developing our environmental, social and governance strategy, which will enable MSD to continue our exemplary legacy of being a force for good in the world. I am grateful to her for her leadership and for her many contributions to our company and global health.”
For over 130 years, MSD has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of our mission to save and improve lives. We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships. Today, MSD continues to be at the forefront of research to prevent and treat diseases that threaten people and animals – including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases – as we aspire to be the premier research-intensive biopharmaceutical company in the world. For more information, visit www.msd.com and connect with us on Twitter, LinkedIn and YouTube.
Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2021 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).
Melissa Moody 215-407-3536
Johanna Herrmann 617-216-6029
Peter Dannenbaum 908-740-1037
Steve Graziano 908-740-6582